Back to Current Sarcoma Research

ASSG Endorsed Clinical Study

ASSG03-10 AYA PK

Title Pharmacokinetics and Pharmacodynamics of Doxorubicin in Children, Adolescents and young adults with Newly Diagnosed Osteosarcoma, Ewing Family of Tumours and Hodgkin Lymphoma
Objective To evaluate the effect of gender on the pharmacokinetics (PK) of doxorubicin in AYA patients with newly diagnosed Ewing family of tumours, Osteosarcoma or Hodgkin lymphoma
Type Pharmacokinetic and Pharmacodynamic
Population This study will recruit patients with osteosarcoma, Ewing family of tumours and Hodgkin lymphoma, across paediatric and adult oncology sites where doxorubicin treatment regimens are accepted standard of care
Treatment N/A
Phase II
Drug / Intervention N/A
Sponsor ASSG Collaborative Group (Academic)
Funding Source Victorian Cancer Agency
Target accrual 210 estimated
Expected Completion 2016
Participating Sites Border Medical Oncology, Wodonga
Children's Hospital Westmead, Sydney
Peter MacCallum Cancer Centre, Melbourne
Royal Children's Hospital, Melbourne
Auckland City Hospital, Auckland
Princess Alexandra Hospital, Brisbane
Lady Cilentro Children's Hospital
University College London Hospital, London Starship, Auckland Lifehouse, Sydney
Recruitment Status Closed
Numbers Accrued 79
Publications and Presentations
 
Principal Investigator Associate Professor David Thomas
Contact for Further Information Linda Cowan - Trial Manager
Contact Phone Number +61 3 9656 3637
linda.cowan@petermac.org
Last update 01-Aug-2017 02:55 PM 

 

biospecimen
Clinical  Data
Contact ASSG